BR112022004534A2 - Anticorpos de domínio único direcionados contra lilrb2 - Google Patents
Anticorpos de domínio único direcionados contra lilrb2Info
- Publication number
- BR112022004534A2 BR112022004534A2 BR112022004534A BR112022004534A BR112022004534A2 BR 112022004534 A2 BR112022004534 A2 BR 112022004534A2 BR 112022004534 A BR112022004534 A BR 112022004534A BR 112022004534 A BR112022004534 A BR 112022004534A BR 112022004534 A2 BR112022004534 A2 BR 112022004534A2
- Authority
- BR
- Brazil
- Prior art keywords
- directed against
- single domain
- domain antibodies
- antibodies directed
- lilrb2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306148 | 2019-09-20 | ||
| PCT/EP2020/076198 WO2021053199A1 (en) | 2019-09-20 | 2020-09-18 | Single-domain antibodies directed against lilrb2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022004534A2 true BR112022004534A2 (pt) | 2022-06-07 |
Family
ID=68654426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004534A BR112022004534A2 (pt) | 2019-09-20 | 2020-09-18 | Anticorpos de domínio único direcionados contra lilrb2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235050A1 (https=) |
| EP (1) | EP4031572A1 (https=) |
| JP (1) | JP7627687B2 (https=) |
| KR (1) | KR20220128332A (https=) |
| CN (1) | CN115066435B (https=) |
| AU (1) | AU2020351274A1 (https=) |
| BR (1) | BR112022004534A2 (https=) |
| CA (1) | CA3154450A1 (https=) |
| IL (1) | IL291506A (https=) |
| MX (1) | MX2022003365A (https=) |
| WO (1) | WO2021053199A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116333127B (zh) * | 2022-06-28 | 2026-03-24 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN115975029A (zh) * | 2022-06-28 | 2023-04-18 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN119604531A (zh) * | 2022-07-29 | 2025-03-11 | 盛禾(中国)生物制药有限公司 | 一种抗ilt4的单域抗体及其应用 |
| CN119768432A (zh) * | 2022-08-22 | 2025-04-04 | 德琪(杭州)生物有限公司 | 新颖的抗lilrb2抗体和其用途 |
| WO2024108568A1 (zh) * | 2022-11-25 | 2024-05-30 | 深圳先进技术研究院 | 抗人类白细胞抗原-g纳米抗体及其制备方法与应用 |
| CN116789825A (zh) * | 2023-05-12 | 2023-09-22 | 南京师范大学 | 抗lilrb1/lilrb2的全人源单域抗体及其应用 |
| CN116789826A (zh) * | 2023-05-12 | 2023-09-22 | 南京师范大学 | 抗人lilrb2全人源单域抗体及其应用 |
| CN119176874A (zh) * | 2023-06-21 | 2024-12-24 | 康源博创生物科技(北京)有限公司 | 一种能够结合lilrb2的抗体或其抗原结合片段 |
| CN119619509A (zh) * | 2023-09-05 | 2025-03-14 | 中日友好医院(中日友好临床医学研究所) | 一种结直肠癌治疗靶点和血清标志物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CA2687633A1 (en) * | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
| WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
| WO2016111947A2 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA2977544C (en) * | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| EA202091540A1 (ru) * | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
| CN111867614A (zh) * | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | 抗lilrb抗体及其用途 |
-
2020
- 2020-09-18 EP EP20771598.8A patent/EP4031572A1/en active Pending
- 2020-09-18 AU AU2020351274A patent/AU2020351274A1/en active Pending
- 2020-09-18 KR KR1020227012733A patent/KR20220128332A/ko active Pending
- 2020-09-18 US US17/762,270 patent/US20230235050A1/en active Pending
- 2020-09-18 JP JP2022517990A patent/JP7627687B2/ja active Active
- 2020-09-18 BR BR112022004534A patent/BR112022004534A2/pt unknown
- 2020-09-18 CA CA3154450A patent/CA3154450A1/en active Pending
- 2020-09-18 WO PCT/EP2020/076198 patent/WO2021053199A1/en not_active Ceased
- 2020-09-18 CN CN202080065196.6A patent/CN115066435B/zh active Active
- 2020-09-18 MX MX2022003365A patent/MX2022003365A/es unknown
-
2022
- 2022-03-20 IL IL291506A patent/IL291506A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115066435A (zh) | 2022-09-16 |
| JP7627687B2 (ja) | 2025-02-06 |
| JP2022548764A (ja) | 2022-11-21 |
| CA3154450A1 (en) | 2021-03-25 |
| EP4031572A1 (en) | 2022-07-27 |
| WO2021053199A1 (en) | 2021-03-25 |
| AU2020351274A1 (en) | 2022-05-05 |
| US20230235050A1 (en) | 2023-07-27 |
| KR20220128332A (ko) | 2022-09-20 |
| IL291506A (en) | 2022-05-01 |
| MX2022003365A (es) | 2022-08-22 |
| CN115066435B (zh) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004534A2 (pt) | Anticorpos de domínio único direcionados contra lilrb2 | |
| CY1123783T1 (el) | Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου | |
| EP3902834A4 (en) | HETERODIMERS TETRAVALENTS AND SPECIFIC ANTIBODY COMPOSITIONS AND USES THEREOF | |
| WO2020198403A3 (en) | Compositions comprising modified circular polyribonucleotides and uses thereof | |
| BR112021026517A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112022003147A2 (pt) | Novos anticorpos anti-cldn18.2 | |
| CL2018002874A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos | |
| BR112019022321A2 (pt) | Tcr e peptídeos | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| MA52288A (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| BR112019002734A2 (pt) | tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart | |
| BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
| MX2020007731A (es) | Compuestos moduladores de receptor de estrogeno. | |
| CY1125348T1 (el) | Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης | |
| EP3777866A4 (en) | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | |
| MX2021015961A (es) | Moleculas novedosas. |